

















Optimal deep brain stimulation site and
target connectivity for chronic cluster
headache
ABSTRACT
Objective: To investigate the mechanism of action of deep brain stimulation for refractory chronic
cluster headache and the optimal target within the ventral tegmental area.
Methods: Seven patients with refractory chronic cluster headache underwent high spatial and
angular resolution diffusion MRI preoperatively. MRI-guided and MRI-verified electrode implanta-
tion was performed unilaterally in 5 patients and bilaterally in 2. Volumes of tissue activation were
generated around active lead contacts with a finite-element model. Twelve months after surgery,
voxel-based morphometry was used to identify voxels associated with higher reduction in head-
ache load. Probabilistic tractography was used to identify the brain connectivity of the activation
volumes in responders, defined as patients with a reduction of $30% in headache load.
Results: There was no surgical morbidity. Average follow-up was 34 6 14 months. Patients
showed reductions of 76 6 33% in headache load, 46 6 41% in attack severity, 58 6 41%
in headache frequency, and 51 6 46% in attack duration at the last follow-up. Six patients
responded to treatment. Greatest reduction in headache load was associated with activation in
an area cantered at 6 mm lateral, 2 mm posterior, and 1 mm inferior to the midcommissural point
of the third ventricle. Average responders’ activation volume lay on the trigeminohypothalamic
tract, connecting the trigeminal system and other brainstem nuclei associated with nociception
and pain modulation with the hypothalamus, and the prefrontal and mesial temporal areas.
Conclusions:We identify the optimal stimulation site and structural connectivity of the deep brain
stimulation target for cluster headache, explicating possible mechanisms of action and disease
pathophysiology. Neurology® 2017;89:1–9
GLOSSARY
AC-PC5 anterior commissure–posterior commissure; CCH5 chronic cluster headache; CH5 cluster headache;DBS5 deep
brain stimulation; HAL 5 headache load; MCP 5 midcommissural point; MNI 5 Montreal Neurological Institute; MPRAGE 5
magnetization-prepared rapid gradient-echo; THT 5 trigeminohypothalamic tract; VTA 5 ventral tegmental area.
Long-term, high-frequency deep brain stimulation (DBS) in the ventral tegmental area (VTA)
has been shown to be a safe and effective treatment modality for patients with refractory chronic
cluster headache (CCH).1–3
The underlying pathophysiology in cluster headache (CH) is not fully understood.4 The
hypothalamus has been implicated in the disease process,5 and pathologic activation of the
trigemino-parasympathetic brainstem reflex is thought to be responsible for simultaneous acti-
vation of trigeminal nerve and craniofacial parasympathetic nerve fibers, respectively, leading to
the characteristic ipsilateral cranial pain and autonomic features.6,7
The periodicity of individual attacks, the relapsing-remitting course, and the seasonal recur-
rence of headache bouts are suggestive of hypothalamic involvement.7 This is supported by
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neuroendocrinological8 and neuroimaging
studies.5,9 The area referred to in the neuro-
imaging studies has been described as the pos-
terior hypothalamus, although the locus of
maximum activation lies in the VTA.3,10
The exact mode of action of DBS for CH
and the neural networks involved remain
poorly understood. Furthermore, the optimal
stimulation site is yet to be identified.2,10–12
Activation of the trigeminal nerve and
ganglion has been demonstrated with hypo-
thalamic stimulation,13 possibly mediated by
the trigeminohypothalamic tract (THT)
described in nonhuman studies.14,15
The objectives of this study were to identify
the optimal VTA stimulation site for improve-
ment in headache load (HAL) and to explore
the connectivity or fingerprint of stimulation
tissue volumes in responders to identify the
THT by proceeding through the following
steps: generating volume of tissue-activated
models for all active DBS contacts, carrying
out a voxel based morphometry–style regres-
sion analysis of modeled activation volumes
and their associated efficacy profiles, and per-
forming tractography from modeled activation
volumes of active DBS contacts in responders
using a probabilistic approach and state-of-the-
art high angular resolution diffusion imaging.
METHODS Standard protocol approvals, registrations,
and patient consents. This study received ethics approval from
the West London NHS Research Ethics Committee (10/H0706/
68). All patients provided written consent.
Patients. Seven patients (5 male) were recruited. Five patients
belonged to a cohort that has been published previously concern-
ing the efficacy and safety of DBS for CCH.3 All patients fulfilled
the International Classification of Headache Disorders-2 and
-3beta diagnostic criteria for CCH and had experienced highly
disabling, medically refractory symptoms for at least 2 years.16,17
All patients had failed to respond to medical therapy trials.
Selection criteria have been described elsewhere.3 Inclusion in the
present study was limited to patients who could tolerate lying flat
for the duration of the preoperative scan and who had no con-
traindications to 3T MRI.
Preoperative MRI data acquisition. Imaging pertinent to this
study was performed before surgery on a 3T Siemens Magnetom-
Trio (Erlangen, Germany) with a 32-channel receive head coil.
Padding was used inside the head coil to reduce discomfort and
head motion.
Diffusion-weighted MRI. Diffusion images were acquired
with a Siemens 511E Advanced Echo Planar Imaging Diffusion
WIP. In-plane acceleration was used (generalized autocalibrat-
ing partially parallel acquisitions factor of 2) with partial Fourier
6/8. In-plane resolution was 1.53 1.5 mm2 (field of view 2193
219 mm2, repetition time 12,200 milliseconds, echo time 99.6
milliseconds), and 85 slices were acquired with a 1.5-mm
thickness. Diffusion weighting with b 5 1,500 s/mm2 was
applied along 128 directions uniformly distributed on the sphere,
and 7 b 5 0 seconds volumes were also acquired. To correct for
distortions, all acquisitions were repeated with a reversed phase-
encoding direction (left-to-right and right-to-left phase encode),
giving a total of 270 volumes acquired ([128 1 7] 3 2). Total
acquisition time was 62 minutes.
The surgical procedure, intraoperative MRI acquisition, and
postoperative DBS programming have been previously described
elsewhere.3 This included stereotactic magnetization-prepared
rapid gradient-echo (MPRAGE) images before and after DBS
lead implantation.
Outcome measures and follow-up. Outcome data were col-
lected and recorded prospectively. These included daily attack fre-
quency, attack severity, attack duration, HAL, and adverse events
(including surgical complications, stimulation-induced adverse
events, and morbidity). Headache severity was measured on the
verbal rating scale for pain (0 being no pain and 10 being
the worst pain imaginable). Attack frequency was defined as the
number of CH attacks per day and duration as the time in hours
of each recorded attack. The individual scores from both were
then averaged over the 2-week observation period. HAL was
defined as S (severity [on the verbal rating scale])3 (duration [in
hours]) of all headache attacks occurring over a 2-week period.
We introduced this measure previously and suggested that it
effectively reflects response to treatment.3 These measures were
assessed with 2-week headache diaries collected preoperatively
(baseline); at the beginning of DBS therapy; at 3, 6, and
12 months; and yearly thereafter.
Responders were defined as patients with sustained HAL
reduction $30% because this was deemed meaningful in line
with the Initiative on Methods, Measurement, and Pain Assess-
ment in Clinical Trials guidelines.18
Analysis of activation volumes. DBS contacts volume of
tissue-activated modeling. SureTune (Medtronic Inc,Minneapolis,
MN), a DBS therapy planning platform, was used to model activation
volumes around individual contacts. The platform applies neuron
models coupled to finite-element simulations as described by
Åström and colleagues19 to generate DBS therapy activation volumes.
After implantation, stereotactic MPRAGE scans were coregistered
with preimplantation stereotactic MPRAGE scans and realigned with
a plane parallel to the anterior commissure–posterior commissure
(AC-PC) line.
The postimplantation MPRAGE was used to fit the DBS lead
model within the MRI artifact produced by the leads. Activation
volumes were generated around active DBS contacts with corre-
sponding voltages.
Interparticipant alignment. Preimplantation MPRAGE
scans were brain extracted with the Brain Extraction Tool (FSL
version 5.0). A 2-step procedure was used to register native
scans to the Montreal Neurological Institute (MNI) 152
standard-space T1-weighted average structural template image
(1-mm resolution). The first step used a linear (affine) trans-
formation with FLIRT (Centre for Functional MRI of the Brain’s
Linear Image Registration Tool) using 12 df. The output from
this step was used to execute nonlinear registration (second step)
with FNIRT (Centre for Functional MRI of the Brain’s Non-
Linear Image Registration Tool). This process produced indi-
vidual native-to-standard (MNI space) nonlinear warp fields that
were then applied to the DBS activation volumes acquired from
SureTune to transform all volumes to standard space.
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Average DBS activation volume and efficacy cluster. All
lateralized volumes (right-sided volumes were flipped to left) were
merged with Fslmerge (FSL version 5.0) into a 4-dimensional
data file. A single-group average (1-sample t test) general linear
model design was used to test against percentage improvement in
HAL.
Nonparametric permutation inference was then carried out
on each voxel with Randomise (FSL version 5.0) with 5,000 per-
mutations to build up the null distribution to test against. Per-
centage improvement in HAL was demeaned, and single-group
t test with threshold-free cluster enhancement was used as the test
statistic. Cluster-based inference with Cluster (FSL version 5.0)
was carried out to extract the clusters and local maxima in
outputs.
Tractography from modeled activation volumes. See the
supplemental material at Neurology.org for diffusion preprocessing.
Probabilistic tractography was generated in ProbtrackX2
GPU version (FSL version 5.0) (number of samples 5,000,
curvature threshold 0.2, step length 0.5 mm, subsidiary fiber
volume fraction threshold 0.01). The process repetitively
samples from the distributions of voxel-wise principal diffusion
directions generated in BedpostX, each time computing
a streamline through these local samples to generate a “probabi-
listic streamline” or a sample from the distribution on
the location of the true streamline, building up a spatial
“connectivity distribution.” Streamlines truly represent paths
of minimal hindrance to diffusion of water in the brain, but
they are reasonable indirect estimates of long-range white mat-
ter connections.20
Probabilistic tractography was generated for all responders
with the DBS activation volume as seeds and the cerebellum
and contralateral hemisphere as the exclusion mask. CSF termina-
tion masks were used to exclude false-positive streamlines.
RESULTS Patients. Scanning and surgery proceeded
with no adverse effects. The mean (SD) follow-up
was 33 (14) months (median 34 months). Six pa-
tients responded to DBS. The patient who did not
respond (CH2) was also the only patient to have
received occipital nerve stimulation before DBS.
This was removed after 5 years for lack of response.
There was no surgical morbidity or mortality. Two
patients with side-alternating attacks underwent
bilateral surgery in 1 episode, bringing the total to
9 implanted DBS leads in this series. Table 1 shows
demographics, disease duration, length of follow-up,
stimulation amplitudes, and change in HAL, attack
Table 1 Patients’ demographics, disease duration, length of follow-up, stimulation amplitudes, and outcome after surgery
Patient
Mean SD MedianCH1 CH2 CH3 CH4 CH5 CH6 CH7
Sex F M M M M F M
Age, y 50 47 56 45 47 61 42 50 7 47
Duration of symptoms, y 5 21 9 4 10 16 25 13 8 10
Side R L L Bilat R Bilat L
Length of follow-up, mo 48 34 33 48 41 14 14 33 14 34
HAL
Before treatment 696 756 720 967 461 520 983 729 199 720
After treatment 70 588 0 0 18 294 146 159 216 70
IMP% 90 15 100 100 96 43 85 76 33 90
Severity (VAS)
Before treatment 9 9 10 10 6 10 6 9 2 9
After treatment 7 7 0 0 4 8 6 4 4 6
IMP% 22 22 100 100 33 20 0 46 41 22
Frequency, d
Before treatment 3 2 2 7 3 9 2 5 3 3
After treatment 3 2 0 0 0.43 5 1 2 2 1
IMP% 0 0 100 100 86 44 50 58 41 50
Duration, min
Before treatment 180 180 180 150 120 30 300 147 83 180
After treatment 45 180 0 0 100 30 90 53 60 45
IMP% 75 0 100 100 17 0 70 51 46 70
Patient-estimated IMP% 60 15 100 100 65 60 30 66 31 60
DBS amplitude, V 3.5 2.4 3 3.5 3.7 3.6 3.5 3.3 0.5 3.5
Abbreviations: Bilat 5 bilateral; DBS 5 deep brain stimulation; HAL 5 headache load; IMP% 5 percentage of improvement; VAS 5 verbal rating scale.
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severity, attack frequency, and attack duration at
the final follow-up from baseline, along with pa-
tient’s estimated percentage of improvement after
surgery.
Stimulation-induced adverse events. There were no seri-
ous adverse effects from DBS. Two patients devel-
oped transient dizziness; 1 patient developed
nausea; and 1 patient developed intermittent diplo-
pia. All were improved with adjustment of the stimu-
lation amplitude. One patient (CH2) developed
troublesome diplopia, oscillopsia, and nystagmus
with DBS amplitudes .2 V.
DBS activation volume modeling and efficacy cluster.
Responders’ average DBS activation volume, nonres-
ponder’s (CH2’s) DBS activation volume, and statis-
tically significant cluster correlated to higher
stimulation efficacy (improvement in HAL) are
shown in figure 1. The responders’ average activation
volume lies in the VTA in the area between the red
nucleus and the mammillothalamic tract. The cluster
predictive of improvement in HAL lies in the supe-
rior, posterior, and lateral portion of the group
average activation volume. The activation volume
for the nonresponder lies outside the efficacy cluster.
Table 2 give average activation and cluster volumes
with MNI coordinates.
Tractography. Group average streamlines generated
from individual responders’ DBS activation volume
are shown in figure 2. Anteriorly, the streamlines
traverse the hypothalamus and then split into 2 path-
ways: an inferolateral pathway toward the mesial tem-
poral lobe and amygdalar complex, possibly via the
amygdalofugal pathway, and an anterosuperior path-
way toward the prefrontal area via the anterior limb of
the internal capsule. Posteriorly, the streamlines run
medial to the red nucleus toward the periaqueductal
gray and then caudally through the pons and upper
medulla in a dorsolateral position toward the trigem-
inal tract and nuclei.
DISCUSSION Voxel-based statistical analysis of
active DBS contacts activation volumes at the last
follow-up point after VTA DBS was used in 7 pa-
tients with medically refractory CCH to identify
a statistically significant cluster in the stimulation
Figure 1 DBS activation volume and efficacy cluster
Average DBS activation volume (green) with DBS efficacy cluster (red) and activation volume for the nonresponder (blue).
DBS 5 deep brain stimulation.
4 Neurology 89 November 14, 2017
area, reflecting the highest-efficacy zone. The res-
ponders’ activation volumes (6 patients, 8 DBS
contacts) were also used to generate probabilistic
tractography streamlines to identify the THT.
We show that patients were appropriately selected
(table 1) as demonstrated in disease duration and
headache characteristics. Furthermore, 6 of 7 patients
had indeed responded well to DBS as demonstrated
by the improvement in HAL, duration, frequency,
and severity.
The first patient21 and patient series1 to undergo
DBS for CCH had the target in what was called the
hypothalamic gray. The target came to light after
a PET study found increased activation in this area
in patients with CH during attacks.9 The target in
this area, which we identify as the VTA, is not readily
Figure 2 Probabilistic tractography streamlines
Group average probabilistic tractography streamlines (red-yellow) with group average deep brain stimulation tissue activa-
tion volume (green).
Table 2 Group average activation volume and high-efficacy cluster with MNI (AC-PC) coordinates of maximum
intensity and center of gravity (left hemisphere)
DBS cluster Volume, mm3
Maximum intensity coordinates Center of gravity coordinates
p Value
MNI (AC-PC) MNI (AC-PC)
x y z x y z
Average responders 254 23 (23) 213 (22) 28 (23) 24 (24) 212 (21) 28 (23) —
Maximum efficacy 14 26 (26) 213 (22) 26 (21) 24 (24) 212 (21) 25 (0) ,0.001
Abbreviations: AC-PC 5 anterior commissure–posterior commissure; DBS 5 deep brain stimulation; MNI 5 Montreal
Neurologic Institute.
AC-PC coordinates are in relation to midcommissural point.
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demarcated. This is due to 3 factors; first, the target
has to be identified with the use of surrounding land-
marks on MRI (e.g., red nucleus, mammillothalamic
tract); second, the stimulation amplitude (an average
of 3.3 V in this study) covers a comparatively large
brain tissue area around the active DBS contact,
hence allowing some leeway in targeting accuracy;
and third, PET studies are subject to misalignment
during the coregistration process, potentially intro-
ducing a spatial error.22 This has been reflected in
the discrepancy in the reported coordinates of activa-
tion with another PET study23 and with an fMRI
study.24
The coordinates of the original target were 2 mm
lateral to the midline, 6 mm behind the midcommis-
sural point (MCP) and 8 mm below the AC-PC.21
This is the same area identified in an earlier PET
study.9 The target was then modified to 2 mm lateral
to the midline, 3 mm posterior, and 5 mm below the
MCP.1 This last Franzini target has generally been
adopted by other groups.12
A study of 10 patients with CCH implanted with
unilateral DBS leads using the Franzini target used
postoperative AC-PC coordinates of the active DBS
contact centers projected on the Schaltenbrand atlas
and a 3-dimensional 4.7T MRI atlas of the
diencephalon-mesencephalic junction atlas to iden-
tify the anatomic location of the effective DBS elec-
trodes.12 Five patients responded to treatment. The
mean coordinates of the active contacts in the res-
ponders were 3 mm lateral, 3.5 mm posterior, and
3.3 mm below the MCP. The study, however, did
not find a statistically significant difference between
the responder and nonresponder groups. The authors
pointed out the limitation of the method used to
localize the contacts, i.e., projection of AC-PC coor-
dinates on atlases.12 These coordinates are within
1.5 mm from the coordinates of the average volume
of DBS activation (maximum intensity point) in the
responders in our study.
Our voxel-based morphometry regression analysis
shows the coordinates of the higher-efficacy predic-
tive cluster (maximum intensity point) to be further
lateral and superior (6 mm lateral, 2 mm posterior,
and 1 mm inferior to the MCP). This seems to be
supported by the relation of the DBS activation vol-
ume of the single nonresponder in our study to the
efficacy cluster lying outside it, as shown in figure 1.
The difficulty in explaining the mechanism of
action of DBS in CH is partly caused by the lack of
a definitive understanding of the pathophysiologic
process itself.25,26 Some authors suggest that simple
local blockade of the posterior hypothalamic gray or
VTA activity is not a likely mechanism for improve-
ment in headache. However, many patients experi-
ence a microlesion or stun effect with complete
abolition of attacks for a few days or even weeks after
DBS lead implantation alone, suggesting disruption
of pathologic neural activity in the region.3,7,25 How-
ever, this does not explain the latency in achieving
maximal DBS efficacy that has been seen across sev-
eral studies, including our own. Increased threshold
for cold pain at the site of the first trigeminal branch
ipsilateral to the stimulated side in patients stimulated
long-term could be caused by modulation of the anti-
nociceptive system27; however, a generic antinocicep-
tive effect does not explain why DBS is effective for
the trigeminal autonomic cephalalgias but not atypi-
cal facial pain.7,25,26 DBS has been shown to modulate
a complex network of pain-processing areas.13 Stim-
ulation induced local activation around the active
DBS contact and distant activation in the ipsilateral
thalamus, somatosensory cortex and precuneus, ante-
rior cingulate cortex, and ipsilateral trigeminal
nucleus and ganglion, coupled with deactivation in
the middle temporal gyrus, posterior cingulate cortex,
inferior temporal gyrus bilaterally, and contralateral
anterior insula.13 This study was the first to document
a functional connection between the hypothalamus
and the trigeminal system in humans in vivo. The
activation in the trigeminal system, however, does
not seem to provoke CH pain attacks or the typical
sensations that commonly accompany trigeminal acti-
vation.13 This connection has been previously
observed after injection of the neuropeptide orexin
B into the posterior hypothalamic region of the rat,
which increased spontaneous activity in the caudal
trigeminal nucleus (with discharges persisting for
several minutes) and heightened responses in the
nucleus to dural stimulation and noxious thermal
stimulation of the face.15
The connection between the trigeminal system
and the hypothalamus is crucial in integrating
somatosensory and visceral information (e.g., inner-
vation from cranial skin, intracranial blood vessels,
and meninges) with endocrine and autonomic re-
sponses.14 Single-unit recording and antidromic mi-
crostimulation techniques in rats have established
a direct 2-way connection between the posterior
hypothalamus and the spinal trigeminal nucleus
through the THT.14
Other brainstem nuclei have neurons that respond
to noxious and innocuous somatosensory and visceral
stimulation. These nuclei also give efferents to the
hypothalamus such as the parabrachial nuclei,28
nucleus of the solitary tract,29 periaqueductal gray,30
and caudal ventrolateral medulla,31 suggesting that
somatosensory signals reach the hypothalamus
through several polysynaptic pathways.14
Previous work has explored the structural connec-
tivity of the DBS target using probabilistic tractogra-
phy in healthy controls.32 Comparable connections to
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the frontal and temporal areas were described along-
side connections to the periaqueductal gray. At the
time, image acquisition parameters were not suffi-
cient for accurate tracking in the brainstem, which
we present here.
Our tractography results show that the DBS-
activated area posterior to the hypothalamus in the
ventral tegmentum lies on a tract that connects the
hypothalamus, prefrontal, and mesial temporal re-
gions anteriorly with brainstem areas in the proximity
of the parabrachial nuclei, nucleus of the solitary
tract, periaqueductal gray, and ending in the region
of the trigeminal nucleus and tract and the superior
salivatory nucleus (figures 2 and 3).
Although this finding does not explain the mech-
anism of action of DBS, it confirms the relevance of
the target site by means of its connections to anatom-
ically relevant brainstem areas. One possibility is the
exertion of a top-down antinociceptive effect; another
possibility is modulation of the trigeminal parasympa-
thetic reflex, commonly activated in primary head-
ache disorders33 and thought to mediate the cranial
autonomic symptoms in CH.34 This pathway can be
triggered by hypodermic capsaicin injection in the
first trigeminal nerve division area35 and a variety of
trigeminal nociceptive triggers.26 Nociceptive trigem-
inal activation, in the first division of the trigeminal
nerve, is relayed into the spinal trigeminal nucleus
and the C1/C2 dorsal horns (i.e., the trigeminocer-
vical complex),36 which has a reflex connection to the
superior salivatory nucleus in the pons.37 The output
is then carried via the parasympathetic pathway of the
facial nerve through the geniculate ganglion within
the greater superficial petrosal nerve38 to the spheno-
palatine ganglion.26,39
It must be noted, however, that the pain and the
autonomic phenomenon can at times occur indepen-
dently,6 especially in patients taking preventive med-
ications, suggesting either anatomically separate
pathways, albeit partly, or different activation thresh-
olds mediating these 2 features.39,40
The largest reduction in HAL after VTA-DBS in
patients with medically refractory CCH appears to
correspond to activation in an area 6 mm lateral,
2 mm posterior, and 1 mm inferior to the MCP.
Active contact DBS activation in responders lies on
Figure 3 Anatomy of the trigeminal nerve and nuclei in the pons
Two cross-sections are shown in the pons at the level of the trigeminal nerve, main sensory, and mesencephalic trigeminal
nuclei (top) and spinal trigeminal nucleus and tract, superior salivatory nucleus, and solitary tract (bottom).
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the THT, connecting the trigeminal system and other
brainstem nuclei linked with nociception and pain
modulation with the hypothalamus and prefrontal
and mesial temporal areas. With only 1 nonre-
sponder, it was not feasible to have a group compar-
ison between responders and nonresponders to show
whether alternative streamlines would be associated
with a negative outcome.
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